{"id":"W2005692436","doi":"10.1158/0008-5472.sabcs13-s5-04","title":"Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Translational Research in Oncology","funders":"","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Clinical endpoint; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Taxane; Placebo; Interim analysis; Phases of clinical research; Progression-free survival; Chemotherapy regimen; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007431141,0.0003551282,0.002297735,0.0005539141,0.0001475564,0.000040643,0.0004109126,0.0001174714,0.003613153],"category_scores_gemma":[0.002048373,0.0002294575,0.0003616551,0.0009978515,0.0006374185,0.0002524266,0.00008589358,0.0007739776,0.0000132138],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009386211,"about_ca_system_score_gemma":0.00170957,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007243609,"about_ca_topic_score_gemma":0.0009530058,"domain_scores_codex":[0.9940407,0.0009100782,0.001803484,0.0006128261,0.001849711,0.0007832158],"domain_scores_gemma":[0.9925353,0.004184495,0.000750727,0.0007623085,0.001528037,0.0002391185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8302693,0.0007965082,0.000009395342,0.0003030606,0.0005818724,0.000005876846,0.001663617,0.001090618,0.05750937,0.00001086939,0.001082309,0.1066772],"study_design_scores_gemma":[0.9838771,0.001546236,0.0008541241,0.001317485,0.0001747433,0.00001049815,0.0003978488,0.00196348,0.008909264,0.0003912837,0.0003510546,0.0002069124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9659253,0.003099991,0.0001890527,0.01074032,0.000210072,0.01868512,0.000698545,0.0000345086,0.0004170814],"genre_scores_gemma":[0.9846668,0.0009576902,0.0004599885,0.0004645464,0.000514185,0.01205165,0.00007254494,0.00007592729,0.0007366975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1536077,"threshold_uncertainty_score":0.9993672,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09301979136539842,"score_gpt":0.4564439374470701,"score_spread":0.3634241460816717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}